title: Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: C W
authors.initials: CW
authors.lastname: Kwon
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Land
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.|Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Smoller
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.|Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: G
authors.initials: G
authors.lastname: Scott
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Beck
authors.affiliation: Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: M G
authors.initials: MG
authors.lastname: Mercurio
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab / Q000009:adverse effects*; D010391:Pemphigoid, Bullous / Q000139:chemically induced*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000074322:Antineoplastic Agents, Immunological; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab